K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · CI
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-21 | CI | CIGNA | CAPITOL HILL CONSULTING GROUP | $50K | Pharmacy issues related to TRICARE. Issues surrounding pharmacy benefit managers, and coverage of biosimilars. |
| 2026-04-20 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | $3.5M | Issues related to prior authorization; ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) model Issues relating to implementation of the No Surprises Act H.R. 3838/S2296 Pharmacy issues related to the National Defense Authorization Act, FY2026 HR. 6400 / S. 4106 - Rx Access, Choice, Cost Equity, and Supply Stability (Rx ACCESS) Act S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act Issues related to competition in the health care marketplace. |
| 2026-04-20 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | $1.7M | Issues related to prior authorization. S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues relating to implementation of the No Surprises Act. H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026. "S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency. Issues related to competition in the health care marketplace. |
| 2026-04-20 | CI | CIGNA CORPORATION AND SUBSIDIARIES | TIBER CREEK GROUP | $90K | Issues related to pharmacy and prescription drug pricing; Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to the extension of Enhanced Advanced Premium Tax Credits (EAPTCs) in the American Rescue Plan Act (PL 117-2) and the Inflation Reduction Act (PL 117-169); Issues relating to implementation of the No Surprises Act (PL 116-260). Pharmacy issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60). Issues related to H.R. 5582/S. 2355 - Patients Deserve Price Tags Act. |
| 2026-04-20 | CI | THE CIGNA GROUP AND SUBSIDIARIES | ATLAS CROSSING LLC | $60K | Issues related to commercial insurance and pharmacy benefits. H.R.4710: No Surprises Act. H.R.7895: PBM Kickback Prohibition Act. |
| 2026-04-19 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FKA CIGNA CORPORATION AND SUBSIDIARIES) | BANNER PUBLIC AFFAIRS, LLC | $20K | Pharmacy issues related to TRICARE; FY2027 Department of Defense Appropriations, FY2027 National Defense Authorization Act Issues related to P.L. 116-260, the No Surprises Act |
| 2026-04-17 | CI | CIGNA CORPORATION | INVARIANT LLC | $90K | Educate lawmakers on issues related to pharmacy benefit managers and drug pricing; proposals impacting employer-sponsored insurance; and proposals related to telehealth. Monitor pharmacy issues related to TRICARE. |
| 2026-04-17 | CI | CIGNA CORPORATION | POLARIS GOVERNMENT RELATIONS, LLC | $90K | Provide advice and counsel on healthcare coverage, surprise billing, drug pricing and Affordable Care Act issues Drug pricing and issues facing the pharmacy benefit manager industry generally |
| 2026-04-17 | CI | CIGNA CORPORATE SERVICES LLC AND ITS AFFILIATES | ALB SOLUTIONS | $50K | Issues related to health care policy including coverage and cost of care. |
| 2026-04-16 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | WILMER CUTLER PICKERING HALE AND DORR LLP | $0 | |
| 2026-04-15 | CI | THE CIGNA GROUP AND SUBSIDIARIES | BELLWETHER GOVERNMENT AFFAIRS LLC | $60K | Strategic and policy advice on issues related to federal tax and health care issues. Strategic and policy advice on issues related to federal tax and health care issues. |
| 2026-04-15 | CI | CIGNA CORPORATE SERVICES LLC AND ITS AFFILIATES | ALB SOLUTIONS | $0 | Issues related to health care policy including coverage and cost of care. |
| 2026-04-13 | CI | THE CIGNA GROUP | RED+BLUE STRATEGIES | $0 | Issues related to pharmacy benefit management services, pharmacy, specialty pharmacy, and individual and group health insurance markets. |
| 2026-04-10 | CI | CIGNA CORPORATE SERVICES LLC AND ITS AFFILIATES | SALT POINT STRATEGIES | $50K | Issues related to health care policy including coverage and cost of care. |
| 2026-01-20 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | $1.6M | Issues related to prior authorization. Issues related to competition in the health care marketplace. S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues relating to implementation of the No Surprises Act. H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026. "S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency. |
| 2026-01-20 | CI | THE CIGNA GROUP AND SUBSIDIARIES | ATLAS CROSSING LLC | $60K | Issues related commercial insurance and pharmacy benefits. |
| 2026-01-20 | CI | CIGNA | CAPITOL HILL CONSULTING GROUP | $50K | Pharmacy issues related to TRICARE. Issues surrounding pharmacy benefit managers, and coverage of biosimilars. Issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs). |
| 2026-01-19 | CI | CIGNA CORPORATION | INVARIANT LLC | $90K | Educate lawmakers on issues related to pharmacy benefit managers and drug pricing; proposals impacting employer-sponsored insurance; and proposals related to telehealth. Monitor pharmacy issues related to TRICARE. |
| 2026-01-18 | CI | THE CIGNA GROUP AND SUBSIDIARIES | BELLWETHER GOVERNMENT AFFAIRS LLC | $110K | Strategic and policy advice on issues related to federal tax and health care issues. Strategic and policy advice on issues related to federal tax and health care issues. |
| 2026-01-18 | CI | CIGNA CORPORATE SERVICES LLC AND ITS AFFILIATES | SALT POINT STRATEGIES | $50K | Issues related to health care policy including coverage and cost of care. |
| 2026-01-18 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | WILMER CUTLER PICKERING HALE AND DORR LLP | $0 | |
| 2026-01-17 | CI | CIGNA CORPORATION AND SUBSIDIARIES | TIBER CREEK GROUP | $90K | Issues related to Medicare drug coverage, specialty pharmacy, and general prescription drug pricing policy; Issues related to the continuation of telehealth flexibilities. Issues related to proposals impacting employer-sponsored insurance; Issues related to pharmacy and prescription drug pricing policy; Issues related to H.R. 247/S. 846 - Health Care Affordability Act of 2025; Issues related to the extension of Enhanced Advanced Premium Tax Credits (EAPTCs) in the American Rescue Plan Act (PL 117-2) and the Inflation Reduction Act (PL 117-169). Pharmacy issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60). |
| 2026-01-16 | CI | CIGNA CORPORATION | POLARIS GOVERNMENT RELATIONS, LLC | $90K | Provide advice and counsel on healthcare coverage, surprise billing, drug pricing and Affordable Care Act issues Drug pricing and issues facing the pharmacy benefit manager industry generally |
| 2026-01-16 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FKA CIGNA CORPORATION AND SUBSIDIARIES) | BANNER PUBLIC AFFAIRS, LLC | $20K | Pharmacy issues related to TRICARE; H.R. 4016 - Department of Defense Appropriations, FY2026; H.R. 3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026; S. 2296 - National Defense Authorization Act for Fiscal Year 2026. Issues related to P.L. 116-260, the No Surprises Act |
| 2025-10-20 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | $1.9M | Issues related to competition in the health care marketplace. P.L. 117-169, the Inflation Reduction Act of 2022; H.R. 4189/S. 2016, The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023; Issues related to transparency and prior authorization. S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation; Issues related to H.R. 2041, the Hidden Fee Disclosure Act of 2025. Pharmacy issues related to the National Defense Authorization Act, FY2026. S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Ac |
| 2025-10-20 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | $1.4M | Issues related to prior authorization. S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation, inclusion of PBM reform and other health policies; Issues relating to implementation of the No Surprises Act. H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026. S. 1542/H.R. 2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market; Issues related to transparency. Issues related to competition in the health care marketplace. |
| 2025-10-20 | CI | THE CIGNA GROUP AND SUBSIDIARIES | BELLWETHER GOVERNMENT AFFAIRS LLC | $90K | Strategic and policy advice on issues related to federal tax and health care issues. Strategic and policy advice on issues related to federal tax and health care issues. |
| 2025-10-20 | CI | THE CIGNA GROUP AND SUBSIDIARIES | ATLAS CROSSING LLC | $60K | Issues related commercial insurance and pharmacy benefits. |
| 2025-10-20 | CI | CIGNA | CAPITOL HILL CONSULTING GROUP | $50K | Pharmacy issues related to TRICARE. Issues surrounding pharmacy benefit managers, and coverage of biosimilars. Issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs). |
| 2025-10-20 | CI | CIGNA CORPORATE SERVICES LLC AND ITS AFFILIATES | SALT POINT STRATEGIES | $50K | Issues related to health care policy including coverage and cost of care. |
| 2025-10-19 | CI | CIGNA CORPORATION AND SUBSIDIARIES | TIBER CREEK GROUP | $90K | Issues related to Medicare drug coverage, specialty pharmacy, and general prescription drug pricing policy. Issues related to proposals impacting employer sponsored insurance; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy and prescription drug pricing policy and telehealth; Issues related to an extension of enhanced premium tax credits and health insurance affordability; Issues related to tax and health coverage changes in the One Big Beautiful Bill Act (PL 119-21); Issues related to competition in the health care marketplace. Pharmacy issues related to H.R. 3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026; Pharmacy issues related to S. 2296 - National Defense Authorization Act for Fiscal Year 2026. |
| 2025-10-17 | CI | CIGNA CORPORATION | POLARIS GOVERNMENT RELATIONS, LLC | $90K | Provide advice and counsel on healthcare coverage, surprise billing, drug pricing and Affordable Care Act issues Drug pricing and issues facing the pharmacy benefit manager industry generally |
| 2025-10-17 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FKA CIGNA CORPORATION AND SUBSIDIARIES) | BANNER PUBLIC AFFAIRS, LLC | $20K | Pharmacy issues related to TRICARE; H.R. 4016 - Department of Defense Appropriations, FY2026; H.R. 3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026; S. 2296 - National Defense Authorization Act for Fiscal Year 2026. Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation. |
| 2025-10-17 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | WILMER CUTLER PICKERING HALE AND DORR LLP | $0 | |
| 2025-10-16 | CI | CIGNA CORPORATION | INVARIANT LLC | $90K | Educate lawmakers on issues related to pharmacy benefit managers and drug pricing; proposals impacting employer-sponsored insurance; proposals related to telehealth. Monitor issues related to Medicare Part D. Monitor pharmacy issues related to TRICARE. |
| 2025-07-21 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | $1.9M | P.L. 117-169, the Inflation Reduction Act of 2022; H.R. 4189/S. 2016, The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023; Issues related to transparency and prior authorization. S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation; Issues related to H.R. 2041, the Hidden Fee Disclosure Act of 2025. Pharmacy issues related to the National Defense Authorization Act, FY2026. S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issue |
| 2025-07-21 | CI | CIGNA | CAPITOL HILL CONSULTING GROUP | $50K | Pharmacy issues related to TRICARE. Issues surrounding pharmacy benefit managers, and coverage of biosimilars. |
| 2025-07-21 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FKA CIGNA CORPORATION AND SUBSIDIARIES) | BANNER PUBLIC AFFAIRS, LLC | $20K | Pharmacy issues related to TRICARE; H.R. 4016 - Department of Defense Appropriations, FY2026; H.R. 3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026; S. 2296 - National Defense Authorization Act for Fiscal Year 2026. S.526 - Pharmacy Benefit Manager Transparency Act of 2025; S. 1339 - Pharmacy Benefit Reform Act (118th Congress); S. 1542/H.R. 2214 - DRUG Act (118th Congress); S. 1038/H.R. 1613 - Drug Price Transparency in Medicaid Act of 2023 (118th Congress); S. 5503/H.R. 10362 - PBM Act of 2024 (118th Congress). |
| 2025-07-20 | CI | CIGNA CORPORATION AND SUBSIDIARIES | TIBER CREEK GROUP | $90K | Issues related to pharmacy, Medicare Part D, and prescription drug pricing policy. Issues related to proposals impacting employer sponsored insurance; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy and prescription drug pricing policy and telehealth; Issues related to an extension of enhanced premium tax credits and health insurance affordability. Issues related to tax and health coverage changes in the One Big Beautiful Bill Act (PL 119-21). Pharmacy issues related to TRICARE. |
| 2025-07-19 | CI | THE CIGNA GROUP AND SUBSIDIARIES | BELLWETHER GOVERNMENT AFFAIRS LLC | $90K | Strategic and policy advice on issues related to federal tax and health care issues. Strategic and policy advice on issues related to federal tax and health care issues. |
| 2025-07-18 | CI | THE CIGNA GROUP AND SUBSIDIARIES | ATLAS CROSSING LLC | $60K | Issues related commercial insurance and pharmacy benefits. |
| 2025-07-17 | CI | CIGNA CORPORATION | INVARIANT LLC | $90K | Educate lawmakers on issues related to pharmacy benefit managers and drug pricing; proposals impacting employer-sponsored insurance; proposals related to telehealth. Monitor issues related to Medicare Part D. Monitor pharmacy issues related to TRICARE. |
| 2025-07-17 | CI | CIGNA CORPORATION | POLARIS GOVERNMENT RELATIONS, LLC | $90K | Provide advice and counsel on healthcare coverage, surprise billing, drug pricing and Affordable Care Act issues Drug pricing and issues facing the pharmacy benefit manager industry generally |
| 2025-07-16 | CI | CIGNA CORPORATE SERVICES LLC AND ITS AFFILIATES | SALT POINT STRATEGIES | $50K | Issues related to health care policy including coverage and cost of care. |
| 2025-07-16 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | WILMER CUTLER PICKERING HALE AND DORR LLP | $0 | |
| 2025-04-21 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | $3.5M | P.L. 117-169, the Inflation Reduction Act of 2022; H.R. 4189/S. 2016, The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023. S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) included in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA). Pharmacy issues related to the National Defense Authorization Act, FY2026. S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S. 526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act. Issues related to H.Con.Res. 14/S.Con.Res. 7 (Establishing the congressional budget for the United States Government for fiscal year 2025) and budget reconciliation; H.R. 1968, Full-Year Continuing Appropriations and Extensio |
| 2025-04-21 | CI | CIGNA CORPORATION | INVARIANT LLC | $90K | Educate lawmakers on issues related to pharmacy benefit managers and drug pricing; proposals impacting employer-sponsored insurance; proposals related to telehealth. Monitor issues related to Medicare Part D. Monitor pharmacy issues related to TRICARE. |
| 2025-04-21 | CI | THE CIGNA GROUP AND SUBSIDIARIES | ATLAS CROSSING LLC | $60K | Issues related commercial insurance and pharmacy benefits. |
| 2025-04-21 | CI | CIGNA | CAPITOL HILL CONSULTING GROUP | $50K | Pharmacy issues related to TRICARE. Pharmacy Benefit Manager. |
| 2025-04-21 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FKA CIGNA CORPORATION AND SUBSIDIARIES) | BANNER PUBLIC AFFAIRS, LLC | $20K | Pharmacy issues related to TRICARE; National Defense Authorization Act for FY2026; H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025; Department of Defense Appropriations, FY2026. S.526 - Pharmacy Benefit Manager Transparency Act of 2025; S. 1339 - Pharmacy Benefit Reform Act (118th Congress); S. 1542/H.R. 2214 - DRUG Act (118th Congress); S. 1038/H.R. 1613 - Drug Price Transparency in Medicaid Act of 2023 (118th Congress); S. 5503/H.R. 10362 - PBM Act of 2024 (118th Congress). |
| 2025-04-20 | CI | CIGNA CORPORATION | POLARIS GOVERNMENT RELATIONS, LLC | $90K | Provide advice and counsel on healthcare coverage, surprise billing, drug pricing and Affordable Care Act issues Drug pricing and issues facing the pharmacy benefit manager industry generally |
| 2025-04-20 | CI | CIGNA CORPORATION AND SUBSIDIARIES | TIBER CREEK GROUP | $90K | Issues related to pharmacy, Medicare Part D, and prescription drug pricing policy. Issues related to proposals impacting employer sponsored insurance; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy and prescription drug pricing policy and telehealth; Issues related to an extension of enhanced premium tax credits and health insurance affordability. Pharmacy issues related to TRICARE. |
| 2025-04-19 | CI | CIGNA CORPORATE SERVICES LLC AND ITS AFFILIATES | SALT POINT STRATEGIES | $50K | Issues related to health care policy including coverage and cost of care. |
| 2025-04-18 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | WILMER CUTLER PICKERING HALE AND DORR LLP | $0 | |
| 2025-04-16 | CI | THE CIGNA GROUP AND SUBSIDIARIES | BELLWETHER GOVERNMENT AFFAIRS LLC | $30K | Strategic and policy advice on issues related to federal tax and health care issues. Strategic and policy advice on issues related to federal tax and health care issues. |
| 2025-03-30 | CI | THE CIGNA GROUP AND SUBSIDIARIES | BELLWETHER GOVERNMENT AFFAIRS LLC | $0 | Strategic and policy advice on issues related to federal tax and health care issues Strategic and policy advice on issues related to federal tax and health care issues |
| 2025-02-24 | CI | CIGNA CORPORATE SERVICES LLC AND ITS AFFILIATES | SALT POINT STRATEGIES | $0 | Issues related to health care policy including coverage and cost of care. |
| 2025-01-21 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | $1.4M | S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R.4881, To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program. Including issues related to point-of-sale rebates in Part D Low-Income Subsidy under the Medicare program; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors Access to Lower Cost Medicines Act of 2023; H.R. 1352, the Increasing Access to Biosimilars Act; H.R. 5386, the Cutting Copays Act; Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Adv |
| 2025-01-21 | CI | THE CIGNA GROUP AND SUBSIDIARIES | ATLAS CROSSING LLC | $60K | Issues related to H.R. 5378, the Lower Costs, More Transparency Act. Issues related commercial insurance and pharmacy benefits. S.150 - Affordable Prescriptions for Patients Act of 2023. Issues related to biosimilar interchangeability. H.R.10545 - American Relief Act, 2025. |
| 2025-01-21 | CI | CIGNA | CAPITOL HILL CONSULTING GROUP | $50K | Pharmacy issues related to TRICARE. Pharmacy Benefit Manager. Medicare Advantage. |
| 2025-01-21 | CI | THE CIGNA GROUP AND SUBSIDIARIES (FKA CIGNA CORPORATION AND SUBSIDIARIES) | BANNER PUBLIC AFFAIRS, LLC | $20K | Pharmacy issues related to TRICARE; Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025 (P.L. 118-159); H.R. 8774/S. 4921: Department of Defense Appropriations Act, FY2025. S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; S. 1339 - Pharmacy Benefit Reform Act; S. 1542 - DRUG Act; H.R. 1613 - Drug Price Transparency in Medicaid Act of 2023; H.R. 10362 - PBM Act of 2024. |
| 2025-01-20 | CI | CIGNA CORPORATION | POLARIS GOVERNMENT RELATIONS, LLC | $90K | Provide advice and counsel on healthcare coverage, surprise billing, drug pricing and Affordable Care Act issues; Drug pricing and issues facing the pharmacy benefit manager industry generally |
| 2025-01-20 | CI | CIGNA CORPORATION | INVARIANT LLC | $90K | Monitor issues related to Medicare Part D and Medicare Advantage. Educare lawmakers on issues related to pharmacy benefit managers and drug pricing; proposals impacting employer-sponsored insurance; proposals related to telehealth; issues related to privacy. Educate lawmakers on pharmacy issues related to TRICARE and H.R. 8070, the Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year. |
| 2025-01-19 | CI | CIGNA CORPORATION AND SUBSIDIARIES | TIBER CREEK GROUP | $90K | Proposals impacting employer sponsored insurance, Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy and prescription drug pricing policy and telehealth in H.R.5378 - Lower Cost, More Transparency Act; H.R.10545 - American Relief Act of 2025 (PL 118-158). Pharmacy issues related to TRICARE in H.R. 8070 - Service Quality of Life Improvement and National Defense Authorization Act of Fiscal Year 2025. Issues related to pharmacy and prescription drug pricing policy in H.R.5378 - Lower Cost, More Transparency Act, and H.R.10545 - American Relief Act of 2025 (PL 118-158). |